Crohn's Disease Forum » Parents of Kids with IBD » Paediatric IBD - Articles and Research


 
05-06-2015, 05:27 PM   #151
crohnsinct
Senior Member
 
Join Date: Mar 2012
Location: California

My Support Groups:
Can't remember if I saw this posted yet or not but an interesting read on the role of diet.

http://journals.lww.com/ibdjournal/F...ics_on.26.aspx
__________________
Daughter O dx 2/1/12 at age 12
Crohns & Remicade induced Psoriasis
Remicade
Vit d 2000IU
Multi vitamin plus iron
Calcium

Previously used - Prednisone, Prevacid, Enteral Nutrition, Methotrexate oral and injections, Folic Acid, Probiotics, Cortofoam

Daughter T dx 1/2/15 at age 11
Vitaligo, Precoscious puberty & Crohn's
Remicade
Vit D 2000IU

Previously used, Exclusive Enteral Nutrition, Methotrexate (injections and oral), Folic Acid, Entocort,IBD-AID Diet
06-15-2015, 08:36 PM   #152
Maya142
Forum Monitor
 
Maya142's Avatar
New drugs (including Entyvio and Simponi):

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451973/
__________________
Mom of M (20)
diagnosed with Crohn's Disease at 16
Juvenile Idiopathic Arthritis at 12
Juvenile Ankylosing Spondylitis at 16

Mom of S (23)
dx with JIA at 14
Ankylosing Spondylitis at 18
07-12-2015, 04:58 PM   #153
crohnsinct
Senior Member
 
Join Date: Mar 2012
Location: California

My Support Groups:
Paper on remicade clearancehttp://www.ncbi.nlm.nih.gov/m/pubmed/25358062/
07-12-2015, 05:39 PM   #154
Mr chicken
Senior Member
 
Mr chicken's Avatar
 
Join Date: May 2015

My Support Groups:
http://www.ncbi.nlm.nih.gov/m/pubmed/25358062/

Fix your link cic
The other one wasn't working since your words blended into the hyperlink
__________________
DS dx at age 7 Crohns
Humira 40 mg every 10 days
Mtx 12.5 mg -due to juvenile spondyloarthritis associated inflammatory bowel disease

Vsl#3ds iron Zantac folic acid


Aka MLP....
07-12-2015, 08:20 PM   #155
crohnsinct
Senior Member
 
Join Date: Mar 2012
Location: California

My Support Groups:
Thanks chickie! Hubby was driving again so I was sticking my nose in the phone and dang those screens are small!
08-02-2015, 05:27 AM   #156
DustyKat
Super Moderator
 
DustyKat's Avatar
 
Join Date: May 2010
Location: New South Wales, Australia
'Biosimilars' for children with IBD need more research, ESPGHAN expert panel states.

Children with inflammatory bowel disease (IBD) who are doing well on specific biological medications should not be switched to recently approved "biosimilar" products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN).
http://www.medicalnewstoday.com/releases/296726.php
__________________
Mum of 2 kids with Crohn's.
09-05-2015, 05:15 AM   #157
Malgrave
Senior Member
 
Malgrave's Avatar
 
Join Date: Jul 2012
Location: Belgium

My Support Groups:
VEO-IBD, very recent article:

http://www.sciencedirect.com/science...52345X15001228
__________________
*Son (9 years) with severe Crohn's diagnosed at the age of 26 months, currently UC or Crohn's colitis
*Current mediacation: IVIG, Humira, Azathpriorine, Eusaprim
(Tested but failed: Modulen IBD, Neocate advance, Budenofalk, Remicade, Azathpriorine, MTX, Jerusalem cocktail, cycklosporine, pentasa,...)
09-10-2015, 11:03 AM   #158
Crohn2357
Senior Member
 
Crohn2357's Avatar
 
Join Date: Aug 2013

My Support Groups:
Researchers Discover Genetic Variants Linked to Very Early Onset IBD in Children

http://ibdnewstoday.com/2015/09/10/c...-ibd-children/

In the study, researchers assessed whether very early onset IBD patients had rare or new variants in genes known to be associated with primary immunodeficiency disorders and related pathways, which could, therefore, contribute to disease development.
The study: Exome Sequencing Analysis Reveals Variants in Primary Immunodeficiency Genes in Patients With Very Early Onset Inflammatory Bowel Disease

http://www.gastrojournal.org/article...-ngf090315.php
10-01-2015, 05:42 PM   #159
Jenn
Senior Member
 
Jenn's Avatar
 
Join Date: Jul 2011
Location: San Diego, California
Interesting article about 4 strains of gut bacteria missing in asthma patients. Wonder if IBD will be soon? Or maybe genetics determine which strains can thrive or not.
http://news.sciencemag.org/biology/2...paign=facebook
__________________
Jennifer ~ son dx at age 8, Sep 2010
currently on Humira, Feb 2012+, MTX (25mg) Aug 2017+, folic acid
past use: 6mp for Sep 2010-Apr 2011 (not effective enough), then Remicade April 2011-Dec 2011 (built antibodies); additional 6MP Aug 2012-Sep 2013; Periactin for appetite Sep 2010-Sep 2013
other: Centrum chewable multi; calcium-vitD;
Derma-Smoothe for psoriasis rashes; Alrex, Zaditor eye drops for vernal conjunctivitis; history of asthma, ear infections
10-09-2015, 03:24 PM   #160
crohnsinct
Senior Member
 
Join Date: Mar 2012
Location: California

My Support Groups:
Combo therapy with biologics and immunomodulator. Good news for the boys!

http://www.ncbi.nlm.nih.gov/pubmed/2...?dopt=Abstract
10-16-2015, 10:54 AM   #161
crohnsinct
Senior Member
 
Join Date: Mar 2012
Location: California

My Support Groups:
Not a ped study but nicely illustrates the point of why we have to go in and look.

http://www.ncbi.nlm.nih.gov/pubmed/26215531
12-07-2015, 08:59 AM   #162
Malgrave
Senior Member
 
Malgrave's Avatar
 
Join Date: Jul 2012
Location: Belgium

My Support Groups:
For this study, the authors performed genetic analysis of 209 patients with very early onset IBD and identified five patients with rare loss-of-function missense mutations in NOX1 or DUOX2. Importantly, these mutations were associated with reduced production of reactive oxygen species (ROS) and defective host resistance to the bacterial pathogen Campylobacter jejuni.

http://www.gastro.org/news_items/201...arly-onset-ibd
02-10-2016, 11:35 AM   #163
Jenn
Senior Member
 
Jenn's Avatar
 
Join Date: Jul 2011
Location: San Diego, California
interesting article on biosimilars and cost
http://www.businessinsider.com/fda-p...similar-2016-2
08-06-2016, 06:18 PM   #164
DustyKat
Super Moderator
 
DustyKat's Avatar
 
Join Date: May 2010
Location: New South Wales, Australia
Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease

Abstract

Background: The efficacy of adalimumab in inducing and maintaining remission in children with moderately to severely active Crohn's disease was shown in the IMAgINE 1 trial (NCT00409682). As per protocol, nonresponders or patients experiencing flare(s) on every other week (EOW) maintenance dosing could escalate to weekly dosing; we aimed to determine the therapeutic benefits of weekly dose escalation in this subpopulation.

Methods: Week 52 remission and response rates were assessed in patients who escalated to weekly dosing from their previous EOW schedule, which was according to randomized treatment dose (higher dose [HD] adalimumab [≥40 kg, 40 mg EOW; <40 kg, 20 mg EOW] or lower dose [LD; ≥40 kg, 20 mg EOW; <40 kg, 10 mg EOW]). Adverse events were reported for patients remaining on EOW dosing and patients receiving weekly dosing.

Results: Escalation to weekly dosing occurred in 48/95 (50.5%) patients randomized to LD and 35/93 (37.6%) patients randomized to HD adalimumab (P = 0.076). Week 52 remission and response rates were 18.8% and 47.9% for patients receiving LD adalimumab weekly and 31.4% and 57.1% for patients receiving HD adalimumab weekly, respectively (LD versus HD, P = 0.19 for remission; P = 0.41 for response). Adverse event rates were similar for patients receiving EOW and weekly adalimumab.

Conclusions: Weekly adalimumab dosing was clinically beneficial for children with Crohn's disease who experienced nonresponse or flare on EOW dosing. No increased safety risks were observed with weekly dosing.
Full Article:
http://journals.lww.com/ibdjournal/F...imumab.13.aspx
08-22-2016, 10:06 AM   #165
xeridea
Senior Member
 
xeridea's Avatar
 
Join Date: Jul 2014

My Support Groups:
I lifted this from xeridea’s thread in the treatment section, thanks xeridea.

4D Pharma announced that they have initiated Phase 1 trial of Thetanix for Pediatric Crohn's Disease. Phase 1 trials are for figuring out the proper/safe dosing levels of a drug.

Here is an excerpt from the top-post for Thetanix, where it was referred to by its pre-clinical development name LBP-001:

Thetanix, comprised of Bacteroides thetaiotaomicron, an obligate anaerobe, is a major endosymbiont of the human gut. Bacteroides thetaiotaomicron is a major component of the adult intestine and has been used as a useful model for the study of human-bacterial symbiosis. Its metabolic function for humans is to degrade plant polysacharides, a very essential capability for the human gut. Additionally, it is very important during the postnatal transition between mother's milk and a diet heavily consisting of plant starches. It has been found to stimulate angiogenesis (growth of new blood vessels from pre-existing vessels) within the gut, due to a microbial signal via bacterial sensing Paneth cells. B. thetaiotaomicron benefits its host by providing sufficient absorptive ability for nutrients the microbe helps process. Another postnatal developmental process within the gut mediated by Bacteroides thetaiotaomicron is the formation of the intestinal mucosal barrier, which helps protect the host against pathogenic invasion via the regulation of the expression of species-specific protein antibiotics. The environment sensing regulatory apparatus present in B. thetaiotaomicron allows for adaptive food seeking, which stabilizes food webs, and subsequently leads to the longevity of communities.

Last edited by DustyKat; 08-23-2016 at 02:14 PM.
08-23-2016, 02:15 PM   #166
DustyKat
Super Moderator
 
DustyKat's Avatar
 
Join Date: May 2010
Location: New South Wales, Australia
Bump - ^^^^
09-26-2016, 07:42 PM   #167
Jenn
Senior Member
 
Jenn's Avatar
 
Join Date: Jul 2011
Location: San Diego, California
biosimilar

http://www.chicagotribune.com/busine...926-story.html
10-10-2016, 02:23 PM   #168
Crohn2357
Senior Member
 
Crohn2357's Avatar
 
Join Date: Aug 2013

My Support Groups:
NOD2 induces autophagy to control AIEC bacteria infectiveness in intestinal epithelial cells

http://link.springer.com/article/10....8?view=classic

Abstract
Objective
The importance of autophagy in mechanisms underlying inflammation has been highlighted. Downstream effects of the bacterial sensor NOD2 include autophagy induction. Recently, a relationship between defects in autophagy and adherent/invasive Escherichia coli (AIEC) persistence has emerged. The present study aims at investigating the interplay between autophagy, NOD2 and AIEC bacteria and assessing the expression level of autophagic proteins in intestinal biopsies of pediatric patients with inflammatory bowel disease (IBD).

Methods
A human epithelial colorectal adenocarcinoma (Caco2) cell line stably over-expressing NOD2 was produced (Caco2NOD2). ATG16L1, LC3 and NOD2 levels were analysed in the Caco2 cell line and Caco2NOD2 after exposure to AIEC strains, by western blot and immunofluorescence. AIEC survival inside cells and TNFα, IL-8 and IL-1βmRNA expression were analysed by gentamicin protection assay and real time PCR. ATG16L1 and LC3 expression was analyzed in the inflamed ileum and colon of 28 patients with Crohn’s disease (CD), 14 with ulcerative colitis (UC) and 23 controls by western blot.

Results
AIEC infection increased ATG16L1 and LC3 in Caco2 cells. Exposure to AIEC strains increased LC3 and ATG16L1 in Caco2 overexpressing NOD2, more than in Caco2 wild type, while a decrease of AIEC survival rate and cytokine expression was observed in the same cell line. LC3 expression was increased in the inflamed colon of CD and UC children.

Conclusions
The NOD2-mediated autophagy induction is crucial to hold the intramucosal bacterial burden, especially towards AIEC, and to limit the resulting inflammatory response. Autophagy is active in inflamed colonic tissues of IBD pediatric patients.

*****
If anyone has access to the full text of this article, please send a message to me. Thanks a lot.
04-08-2017, 12:27 PM   #169
Jenn
Senior Member
 
Jenn's Avatar
 
Join Date: Jul 2011
Location: San Diego, California
Early antibiotic use ( sigh )

http://www.sciencealert.com/antibiot...ur-study-finds
04-15-2017, 06:04 PM   #170
Tesscorm
Moderator
 
Tesscorm's Avatar
 
Join Date: Jun 2011
Location: Ontario

My Support Groups:
Descriptions of remission terms



Mucosal healing and deep remission: What does it mean?
Gerhard Rogler, Stephan Vavricka, Alain Schoepfer, and Peter L Lakatos
Author information ► Article notes ► Copyright and License information ►
This article has been cited by other articles in PMC.
Go to:
Abstract
The use of specific terms under different meanings and varying definitions has always been a source of confusion in science. When we point our efforts towards an evidence based medicine for inflammatory bowel diseases (IBD) the same is true: Terms such as “mucosal healing” or “deep remission” as endpoints in clinical trials or treatment goals in daily patient care may contribute to misconceptions if meanings change over time or definitions are altered. It appears to be useful to first have a look at the development of terms and their definitions, to assess their intrinsic and context-independent problems and then to analyze the different relevance in present-day clinical studies and trials. The purpose of such an attempt would be to gain clearer insights into the true impact of the clinical findings behind the terms. It may also lead to a better defined use of those terms for future studies. The terms “mucosal healing” and “deep remission” have been introduced in recent years as new therapeutic targets in the treatment of IBD patients. Several clinical trials, cohort studies or inception cohorts provided data that the long term disease course is better, when mucosal healing is achieved. However, it is still unclear whether continued or increased therapeutic measures will aid or improve mucosal healing for patients in clinical remission. Clinical trials are under way to answer this question. Attention should be paid to clearly address what levels of IBD activity are looked at. In the present review article authors aim to summarize the current evidence available on mucosal healing and deep remission and try to highlight their value and position in the everyday decision making for gastroenterologists.

Full article:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837253/
__________________
Tess, mom to S
Diagnosed May 2011

Treatment:
May-July 2011 - 6 wks Exclusive EN via NG tube - 2000 ml/night, 1 wk IV Flagyl
July 2011-July 2013 - Supplemental EN via NG, 1000 ml/night, 5 nites/wk, Nexium, 40 mg
Feb. 2013-present - Remicade, 5 mg/kg every 6 wks
Supplements: 1-2 Boost shakes, D3 - 2000 IUs, Krill Oil
04-03-2018, 10:40 PM   #171
Jenn
Senior Member
 
Jenn's Avatar
 
Join Date: Jul 2011
Location: San Diego, California
Stem Cell Therapy for Crohn’s Disease Approved in Europe

https://labiotech.eu/tigenix-alofise...mpression=true
04-10-2018, 08:15 PM   #172
Jenn
Senior Member
 
Jenn's Avatar
 
Join Date: Jul 2011
Location: San Diego, California
Article on the microbiome.
https://www.nytimes.com/2018/04/06/o...sed-foods.html
Reply

Crohn's Disease Forum » Parents of Kids with IBD » Paediatric IBD - Articles and Research
Thread Tools


All times are GMT -5. The time now is 11:40 PM.
Copyright 2006-2017 Crohnsforum.com